-
Views
-
Cite
Cite
Henry W. Murray, Kathleen E. Squires, Walter Weiss, Sandi Sledz, Henry S. Sacks, Joseph Hassett, Anne Cross, Robert E. Anderson, Lisa M. Dunkle, Stavudine In Patients With Aids And Aids-Related Complex: Aids Clinical Trials Group 089, The Journal of Infectious Diseases, Volume 171, Issue Supplement_2, March 1995, Pages S123–S130, https://doi.org/10.1093/infdis/171.Supplement_2.S123
- Share Icon Share
Abstract
In a phase I trial of stavudine in AIDS or AIDS-related complex (ARC), antiviral effects and safety were assessed in 41 patients treated with dosages of 0.5–12.0 mg/kg/day. Among evaluable patients, 10% increases in CD4lymphocyte counts were sustained in 24 (60%) of 40 during treatment; an NAVC response (normalized area under the CD4 cell count-versus-time curve > 1.0) was observed in 31 (91 %) of 34 at 10 weeks and in 20 (80%) of 25 at 24 weeks; 15 (83%) of 18 had decreases in p24 antigenemia; and 24 (60%) of 40 gained >2.5 kg body weight. Median CD4lymphocyte levels remained above baseline for 6 months in patients receiving >0.5 rug/kg/day. Median serum p24 antigen levels remained below baseline for >1 year in patients with p24 antigen responses. The principal toxicity was peripheral neuropathy, which generally resolved after drug discontinuation but limited the dosage to <2.0 rug/kg/day. Additional trials assessing the effect of stavudine on overall morbidity and mortality are ongoing.